On November 4, 2016, Arno Therapeutics, Inc. (OTCPK:ARNI) closed the transaction. The company has issued 1,214,999 units for gross proceeds $425,250 in its last tranche. The company has issued 7,787,136 shares for gross proceeds of $2,725,498.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0003 USD | +417.24% | -.--% | +200.00% |
2017 | Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University | CI |
2017 | Arno Therapeutics Seeks Acquisitions | CI |
1st Jan change | Capi. | |
---|---|---|
+200.00% | 14.8K | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-5.78% | 13.3B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B |
- Stock Market
- Equities
- ARNI Stock
- News Arno Therapeutics, Inc.
- Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC